Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05618379
Active, not recruiting Observational

Adult Spinal Muscular Atrophy (SMA) China Registry

NCT05618379 · tracked via the Priya Life Science China tracker
Sponsor
Biogen
Phase
Observational
Started
2023-01-06
Last updated
2026-08-04

Condition(s) studied

Muscular Atrophy, Spinal

Study summary

The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: -Genetically confirmed 5q-SMA. Key Exclusion Criteria: -Other types of SMA (non 5q-SMA). NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Primary outcome measure(s)

  • Number of Participants Characterized by Natural History of 5q-SMA Observed Among Adult Chinese Participants — Up to 60 Months
    The natural history characteristics will include the categories of the evolution of the patient's condition over the time of data collection from the registry, to describe the natural history of the disease in a real-life situation.
  • Number of Participants Characterized by Utilization of Disease Modifying Therapies (DMTs) of 5q-SMA Observed Among Adult Chinese Participants — Up to 60 Months
    The DMT utilization characteristics will include the categories of the evolution of the DMT treated patient's condition over the time of data collection from the registry, to describe the utilization of DMTs of adult SMA patients in a real-life situation.

Trial sites (12)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing Beijing Municipality
The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian
The First Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong
Peking University Shenzhen Hospital Shenzhen Guangdong
The Second Hospital of Hebei Medical University Shijiazhuang Hebei
Xiangya Hospital of Central South University Changsha Hunan
The First Affiliated Hospital of Soochow University Suzhou Jiangsu
The First Affiliated Hospital of Nanchang University Nanchang Jiangxi
Qilu Hospital of Shandong University Jinan Shandong
Huashan Hospital, Fudan University Shanghai Shanghai Municipality
West China Hospital, Sichuan University Chengdu Sichuan
The First People's Hospital of Yunnan Province Kunming Yun'nan

More Biogen trials in China

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Recruiting
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Active, not recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam Recruiting
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) Active, not recruiting

Other trials for the same condition

Pediatric Spinal Muscular Atrophy (SMA) China Registry Active, not recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05618379 on ClinicalTrials.gov ↗ ← All trials in China